261 related articles for article (PubMed ID: 28880727)
1. Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors.
Monti S; Todoerti M; Codullo V; Favalli EG; Biggioggero M; Becciolini A; Montecucco C; Caporali R
Mod Rheumatol; 2018 May; 28(3):542-549. PubMed ID: 28880727
[TBL] [Abstract][Full Text] [Related]
2. Brief Report: Clinical Course Over Two Years in Patients With Early Nonradiographic Axial Spondyloarthritis and Patients With Ankylosing Spondylitis Not Treated With Tumor Necrosis Factor Blockers: Results From the German Spondyloarthritis Inception Cohort.
Poddubnyy D; Haibel H; Braun J; Rudwaleit M; Sieper J
Arthritis Rheumatol; 2015 Sep; 67(9):2369-75. PubMed ID: 26017497
[TBL] [Abstract][Full Text] [Related]
3. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors.
Pedersen SJ; Sørensen IJ; Hermann KG; Madsen OR; Tvede N; Hansen MS; Thamsborg G; Andersen LS; Majgaard O; Loft AG; Erlendsson J; Asmussen K; Johansen JS; Jurik AG; Møller J; Hasselquist M; Mikkelsen D; Skjødt T; Hansen A; Ostergaard M
Ann Rheum Dis; 2010 Jun; 69(6):1065-71. PubMed ID: 19740906
[TBL] [Abstract][Full Text] [Related]
4. Effects of tapering tumor necrosis factor inhibitor on the achievement of inactive disease in patients with axial spondyloarthritis: a nationwide cohort study.
Park JW; Kim HA; Shin K; Park YB; Kim TH; Song YW; Lee EY
Arthritis Res Ther; 2019 Jul; 21(1):163. PubMed ID: 31272498
[TBL] [Abstract][Full Text] [Related]
5. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study.
Kilic E; Kilic G; Akgul O; Ozgocmen S
Rheumatol Int; 2015 Jun; 35(6):981-9. PubMed ID: 25366469
[TBL] [Abstract][Full Text] [Related]
6. Construct validity of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and Ankylosing Spondylitis Disease Activity Score (ASDAS) treatment target cut-offs in a BASDAI treat-to-target axial spondyloarthritis cohort: a cross-sectional study.
Michielsens C; Bolhuis TE; van Gaalen FA; van den Hoogen F; Verhoef LM; den Broeder N; den Broeder AA
Scand J Rheumatol; 2024 May; 53(3):180-187. PubMed ID: 37339375
[TBL] [Abstract][Full Text] [Related]
7. Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity.
Salaffi F; De Angelis R; Carotti M; Gutierrez M; Sarzi-Puttini P; Atzeni F
Rheumatol Int; 2014 Aug; 34(8):1103-10. PubMed ID: 24509896
[TBL] [Abstract][Full Text] [Related]
8. Validity and reliability of the Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in patients with axial spondyloarthritis (axSpA) in Singapore.
Kwan YH; Tan JJ; Phang JK; Fong W; Lim KK; Koh HL; Lui NL; Tan CS; Østbye T; Thumboo J; Leung YY
Int J Rheum Dis; 2019 Dec; 22(12):2206-2212. PubMed ID: 31721427
[TBL] [Abstract][Full Text] [Related]
9. Construct validity and responsiveness of the simplified version of Ankylosing Spondylitis Disease Activity Score (SASDAS) for the evaluation of disease activity in axial spondyloarthritis.
Salaffi F; Ciapetti A; Carotti M; Gasparini S; Citera G; Gutierrez M
Health Qual Life Outcomes; 2014 Aug; 12():129. PubMed ID: 25146299
[TBL] [Abstract][Full Text] [Related]
10. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
[TBL] [Abstract][Full Text] [Related]
11. Low BASDAI score alone is not a good predictor of anti-tumor necrosis factor treatment efficacy in ankylosing spondylitis: a retrospective cohort study.
Nam B; Koo BS; Lee TH; Shin JH; Kim JJ; Lee S; Joo KB; Kim TH
BMC Musculoskelet Disord; 2021 Feb; 22(1):140. PubMed ID: 33541326
[TBL] [Abstract][Full Text] [Related]
12. Impaired response to treatment with tumour necrosis factor α inhibitors in smokers with axial spondyloarthritis.
Ciurea A; Scherer A; Weber U; Exer P; Bernhard J; Tamborrini G; Riek M; Müller RB; Weiss B; Nissen MJ; Kissling R; Michel BA; Finckh A;
Ann Rheum Dis; 2016 Mar; 75(3):532-9. PubMed ID: 25667205
[TBL] [Abstract][Full Text] [Related]
13. Fibromyalgia in Spondyloarthritis: Effect on Disease Activity Assessment in Clinical Practice.
Wach J; Letroublon MC; Coury F; Tebib JG
J Rheumatol; 2016 Nov; 43(11):2056-2063. PubMed ID: 27633820
[TBL] [Abstract][Full Text] [Related]
14. Tumor Necrosis Factor-α Inhibition in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Treatment Response, Drug Survival, and Patient Outcome.
Corli J; Flipo RM; Philippe P; Bera-Louville A; Béhal H; Wibaux C; Paccou J
J Rheumatol; 2015 Dec; 42(12):2376-82. PubMed ID: 26568593
[TBL] [Abstract][Full Text] [Related]
15. Validity of the ankylosing spondylitis disease activity score (ASDAS) in patients with early spondyloarthritis from the Esperanza programme.
Fernández-Espartero C; de Miguel E; Loza E; Tomero E; Gobbo M; Descalzo MA; Collantes-Estévez E; Mulero J; Muñoz-Fernández S; Zarco P; Carmona L;
Ann Rheum Dis; 2014 Jul; 73(7):1350-5. PubMed ID: 23709245
[TBL] [Abstract][Full Text] [Related]
16. ASDAS high disease activity versus BASDAI elevation in patients with ankylosing spondylitis as selection criterion for anti-TNF therapy.
Vastesaeger N; Cruyssen BV; Mulero J; Gratacós Masmitjá J; Zarco P; Almodovar R; Font P; Juanola X; Collantes-Estevez E;
Reumatol Clin; 2014; 10(4):204-9. PubMed ID: 24598027
[TBL] [Abstract][Full Text] [Related]
17. Sustained low functional impairment in axial spondyloarthritis (axSpA): which are the primary outcomes that should be targeted to achieve this?
Maksymowych WP; Inman RD; Bessette L; Rahman P; Rampakakis E; Asin-Milan O; Rachich M; Marrache AM; Lehman AJ
Arthritis Res Ther; 2023 Apr; 25(1):70. PubMed ID: 37118833
[TBL] [Abstract][Full Text] [Related]
18. Fatigue in Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis: Analysis from a Longitudinal Observation Cohort.
Bedaiwi M; Sari I; Thavaneswaran A; Ayearst R; Haroon N; Inman RD
J Rheumatol; 2015 Dec; 42(12):2354-60. PubMed ID: 26523020
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of switching between TNF inhibitors in patients with axial spondyloarthritis: is the reason to switch relevant?
Manica SR; Sepriano A; Pimentel-Santos F; Gouveia N; Barcelos A; Branco JC; Bernardes M; Ferreira RM; Vieira-Sousa E; Barreira S; Vinagre F; Roque R; Santos H; Madeira N; Rovisco J; Daniel A; Ramiro S
Arthritis Res Ther; 2020 Aug; 22(1):195. PubMed ID: 32825839
[TBL] [Abstract][Full Text] [Related]
20. Relationship between psychiatric status, self-reported outcome measures, and clinical parameters in axial spondyloarthritis.
Kilic G; Kilic E; Ozgocmen S
Medicine (Baltimore); 2014 Dec; 93(29):e337. PubMed ID: 25546683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
